SCHEMBL1395113

SCHEMBL1395113

O=C(O)N1CCC2(CC1)CN(c1cc(F)ccc1Cl)C2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 0.47
ALDH1A1 P00352 7/20 0.47
USP2 O75604 5/20 0.47
HIF1A Q16665 4/20 0.47
CYP1A2 P05177 3/20 0.47
CYP2D6 P10635 3/20 0.47
SCD O00767 2/20 0.44
SCD5 Q86SK9 1/20 0.44
HPGD P15428 5/20 0.44
HSD17B10 Q99714 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPK1 P28482 3/20 0.44
GPR183 P32249 4/20 0.43
HTR1A P08908 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43
TSHR P16473 3/20 0.43
CYP2C19 P33261 3/20 0.42
CYP2C9 P11712 3/20 0.42
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1394929 0.90 SCD (0.47) CYP3A4ALDH1A1USP2HIF1ACYP1A2
SCHEMBL1394565 0.88 SCD (0.48) CYP3A4ALDH1A1USP2HIF1ACYP1A2
SCHEMBL3708569 0.83 SCD5 (0.58) ALDH1A1SCDSCD5SMN1; SMN2HTR1A
SCHEMBL1394169 0.82 HDAC2 (0.51) CYP3A4ALDH1A1USP2SCD5HSD17B10
Trifluoroacetic Acid SCHEMBL1394557 0.80 USP2 (0.42) CYP3A4ALDH1A1USP2HIF1ACYP1A2
SCHEMBL3709763 0.78 SCD5 (0.54) ALDH1A1SCDSCD5SMN1; SMN2HTR1A
Trifluoroacetic Acid SCHEMBL1394390 0.77 SCD (0.42) SCDSCD5HTR1AADRA1AADRA1B
SCHEMBL10112017 0.76 TSHR (0.45) CYP3A4ALDH1A1USP2HIF1ACYP1A2
SCHEMBL1395054 0.76 HDAC2 (0.49) ALDH1A1SCDSCD5GPR183HTR1A
SCHEMBL1394129 0.74 SCD (0.48) CYP1A2SCDSCD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010186-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2012-01-12 US disclosed
WO-2010108268-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-09-30 WO disclosed
WO-2010108268-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010186-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, FASN CYP3A4 828/4885ALDH1A1 544/4885USP2 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.